Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PERPRISE: A Prospective Non-interventional Study Evaluating the Effectiveness of Perampanel (Fycompa) as Only Add-on Treatment in Patients With Primary or Secondarily Generalized Tonic-clonic Seizures

Next Previous
Trial Profile

PERPRISE: A Prospective Non-interventional Study Evaluating the Effectiveness of Perampanel (Fycompa) as Only Add-on Treatment in Patients With Primary or Secondarily Generalized Tonic-clonic Seizures

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Perampanel (Primary)
  • Indications Generalised seizures; Partial epilepsies; Tonic-clonic epilepsy
  • Focus Therapeutic Use
  • Acronyms PERPRISE
  • Sponsors Eisai Inc

Most Recent Events

  • 14 Aug 2023 According to a Catalyst Pharmaceuticals media release, results from this study will be presented at the upcoming 35th International Epilepsy Congress taking place on September 2 - 6, 2023 in Dublin, Ireland
  • 02 Aug 2023 Status changed from active, no longer recruiting to completed.
  • 06 Dec 2022 Results (n=100; As of November 25, 2021) assessing the effectiveness of perampanel as the only adjunctive treatment in adults with FBTCS/GTCS in clinical practice in Germany, presented at the 76th Annual Meeting of the American Epilepsy Society.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top